Teva is prepared to leave no stone unturned in defending itself following the European Commission’s preliminary finding that the Israeli firm breached EU antitrust rules over Copaxone (glatiramer acetate), including by “artificially expanding” the multiple sclerosis treatment’s patent life to delay generic competition.
The commission also alleged that Teva had “systematically spread misleading information about a competing product with a view to hinder...





